Society features

Legend Biotech to Welcome Investors to the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

SOMERSET, NJ–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company that develops, manufactures and markets novel therapies to treat life-threatening diseases, today announced that it will host an event for investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Taking place on Sunday, June 5 at 6 p.m. central time, the meeting will feature Dr. Sundar Jagannath, professor of medicine, hematology and medical oncology at Mount Sinai School of Medicine and director of the multiple myeloma program at Mount Sinai Hospital.

Dr. Jagannath will detail new and updated data from the CARTITUDE clinical development program for ciltacabtagene autoleucel (cilta-cel), an investigational chimeric T-cell therapy for B-cell maturation antigen-directed antigen (BCMA) receptors ( CAR-T) being studied for the treatment of patients with relapsed or refractory multiple myeloma. The meeting will follow the oral and poster presentations of the studies at the ASCO annual meeting.

Investors who cannot attend the event in person can also access it virtually by visiting Events and presentations on the Legend Biotech website.

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating and, one day, curing life-threatening diseases. Based in Somerset, New Jersey, we develop advanced cell therapies on a wide range of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cells, T-cell receptors (TCR-T) and natural killer (NK) cells. based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, effective and cutting-edge therapies for patients around the world.

Learn more about www.legendbiotech.com and follow us on Twitter and LinkedIn.

Caution Regarding Forward-Looking Statements

Statements in this press release regarding future expectations, plans and prospects, and any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives; statements relating to CARVYKTI™, including Legend Biotech’s expectations for CARVYKTI™, such as Legend Biotech’s manufacturing and commercialization expectations for CARVYKTI™ and the potential effect of treatment with CARVYKTI™; statements regarding submissions of cilta-cel to the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), the China Center for Drug Evaluation of the National Medical Products Administration ( CDE) and other regulatory authorities; the expected timing and ability to progress clinical trials, including patient recruitment; submitting Investigational New Drug (IND) applications to regulatory authorities and maintaining such applications with regulatory authorities; the ability to generate, analyze and present clinical trial data; and the potential benefits of Legend Biotech’s product candidates. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, ” predict”, “project”, “should”, “target”, “shall”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties related to the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or data analysis, or government regulation generally; unforeseen delays as a result of actions taken or inaction by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including uncertainties related to the litigation process in the United States; competition in general; government, industry and public awards and other political pressures; the duration and severity of the COVID-19 pandemic and the governmental and regulatory measures put in place in response to the evolving situation; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2022. Should one or more of these risks or uncertainties materialize, or If underlying assumptions prove incorrect, actual results could differ materially from those described in this press release, as anticipated, believed, estimated or expected. All forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.